According to the literature, the prevalence of chronic cholecystitis and gallbladder stones in China is 16.90%. Based on a population of 1.3 billion, there are more than 200 million patients with chronic cholecystitis and gallbladder stones in China. A systematic review of foreign patients with chronic cholecystitis and gallbladder stones with clinical symptoms over 14 years found that 55% of patients were treated conservatively with medications and did not require surgery. The majority of patients with chronic cholecystitis and gallbladder stones clinically wish to receive conservative treatment and first visit internal medicine. However, there is no consensus opinion on the medical treatment of chronic cholecystitis and gallbladder stones at home and abroad, and the scientific process of their diagnosis and treatment is yet to be clarified. The risk of chronic cholecystitis and cholelithiasis increases with the development of the disease, so a clear scientific procedure is not only a clear direction for doctors to treat the disease, but also a reminder for patients to be alert to the disease when there are no symptoms or when the symptoms are not obvious, and to go to internal medicine for diagnosis and early control of the disease. Recently, the Chinese Journal of Gastroenterology published the “Chinese Consensus on Internal Medicine for Chronic Cholecystitis and Gallbladder Stones (2014 Edition)”. The consensus was developed by authoritative experts in gastroenterology and surgery in China based on the epidemiological trends of chronic gallbladder disease in China, the latest research results and evidence-based medicine, and combined with years of clinical trial experience. For patients with asymptomatic chronic cholecystitis and gallbladder stones, treatment principles should combine dietary modification, cholestatic therapy, and prophylactic cholecystectomy. The consensus recommends a low-fat, low-calorie diet and promotes a regular diet at regular intervals. Cholestatic therapy can promote the synthesis and secretion of bile through azinomide, while increasing the activity of pancreatic enzymes and facilitating the absorption of carbohydrates, fats and proteins. Prophylactic cholecystectomy can be performed for high-risk patients who are prone to gallbladder cancer, immunosuppressed patients after organ transplantation, and those who are at increased risk of gallbladder cancer due to “porcelain” gallbladder. For patients with symptomatic chronic cholecystitis and gallbladder stones, treatment should focus on controlling symptoms and eliminating inflammatory reactions. Symptoms of chronic cholecystitis and gallbladder stones are usually treated first with internal medicine, and 10% to 33% of patients with dyspepsia with gallbladder stones have relief of symptoms after cholecystectomy. However, because biliary dyspepsia also has a pathogenesis of extra-biliary digestive system dysfunction, patients need to be treated early with drugs that help improve the symptoms of biliary dyspepsia, such as Azinomide or other pancreatic enzymes, to enhance digestion and improve bloating symptoms and nutritional levels.